Apoptosis of erythroid precursors (annexin V assessment) in patients in group I and group II combined
| Diagnostic category . | No. of patients . | Erythroid precursors undergoing apoptosis (%) . |
|---|---|---|
| Control | 12 | 3.1 ± 1.1 |
| HbH | 6 | 6.2 ± 2.2 |
| HbH/CS | 7 | 4.7 ± 1.8 |
| HbCS/CS | 6 | 10.9 ± 2.9 |
| β-thal/HbE | 15 | 13.2 ± 3.6 |
| Diagnostic category . | No. of patients . | Erythroid precursors undergoing apoptosis (%) . |
|---|---|---|
| Control | 12 | 3.1 ± 1.1 |
| HbH | 6 | 6.2 ± 2.2 |
| HbH/CS | 7 | 4.7 ± 1.8 |
| HbCS/CS | 6 | 10.9 ± 2.9 |
| β-thal/HbE | 15 | 13.2 ± 3.6 |
β-thal/HbE indicates β thalassemia/hemoglobin E. Results of statistical analyses were as follows: control versus HbH,P < .02; control versus HbH/CS, not significant; control versus HbCS/CS, P < .001; control versus β-thal/HbE, P < .00001; β-thal/HbE versus HbH,P < .0001; β-thal/HbE versus HbH/CS,P < .00001; β- thal/HbE versus HbCS/CS, not significant; HbCS/CS versus HbH, P < .01; and HbCS/CS versus HbH/CS, P < .001.